Lilly’s Neutralizing Antibodies Reduce Risk Of Serious COVID-19 Outcomes By 70%

The bamlanivimab/etesevimab combo, filed for US emergency authorization in November, shows ability to reduce risk of hospitalization or death in COVID-19 patients. Lilly also sees prevention role for bamlanivimab.

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease
Lilly says two-antibody regimen against COVID-19 provides significant risk reduction for hospitalization, death

Eli Lilly and Company unveiled data from a trial of more than 1,000 high-risk COVID-19 patients on 26 January that bolsters its case for its neutralizing antibody duo to be deployed to prevent the risk of hospitalization or death in people infected by the novel coronavirus. One noteworthy datapoint showed that no patients who received the regimen died, compared to 10 patients in the placebo group.

Bamlanivimab (LLY-CoV555), co-developed by Lilly and AbCellera Biologics Inc., obtained emergency use authorization (EUA) on 9 November from the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip